ACC
From ACC26, Dr Matt Budoff shared his highlights, including the new cholesterol guidelines and imaging advances position coronary artery calcium scoring at the heart of personalized cardiovascular risk assessment and prevention.
From breakthrough prevention strategies to pivotal late-breaking trials, ACC.26 showcased the rapidly evolving future of cardiovascular care.
At ACC26, Dr Mardi Gomberg-Maitland presented results from the CADENCE trial, showing how sotatercept significantly improves pulmonary hemodynamics in HFpEF-associated pulmonary hypertension, offering hope for the first targeted therapy in this high-risk population.
At ACC26, William Fearon and Ajay Kirtane presented a large randomized trial, showing angiography-derived coronary physiology is noninferior to pressure wire–guided PCI, with added procedural efficiency and potential to expand physiologic assessment in routine practice.
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Despite advancements in mortality rates from cardiovascular disease (CVD) over the last 50 years, it remains the leading cause of death for women and the third leading cause for women aged 18 to 44.1Â A 2011 report from the American Heart Association (AHA) starkly ...
Tricuspid regurgitation (TR) is a frequent finding on echocardiography, with detection rates reaching up to 86% across the different ranges of severity, with moderate or greater TR being reported in at least 6–8% of patients.1–3 The prevalence of TR increases with age, ...
Cardiac complications constitute a common cause of morbidity and mortality in the perioperative period, contributing to over a third of perioperative deaths.1Â More than 230 million major surgeries are performed annually worldwide, with older patients representing an increasing proportion of the ...
As of the publication of this article, the coronavirus disease 2019 (COVID-19) infection has affected over 400 million people around the world and caused over 6 million deaths.1Â Although COVID-19 infection predominantly affects the respiratory system, studies have described a wide spectrum of ...
Tricuspid regurgitation (TR) is a complex disease with several independent causes. Consequently, outcomes and response to therapy vary widely. Severe or progressive TR often results in gradual right ventricular (RV) failure and is associated with poor long-term outcomes.1Â Most cases ...
The SuperWIN study is a supermarket and web-based intervention targeting nutrition. touchCARDIO spoke to Prof Dylan Steen (University of Cincinnati Medical Center, Cincinnati, OH, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022 entitled 'SuperWIN: A ...
The POISE-3 study assessed the effects of a hypotension-avoidance strategy versus a hypertension-avoidance strategy in patients undergoing noncardiac surgery. touchCARDIO spoke to Dr Maura Marcucci (McMaster University, Hamilton, Ontario, Canada) to discuss her presentation of the results of the POSE-3 ...
Both the CoreValve US pivotal and SURTAVI trials investigated the five-year incidence, timing and predictors of haemodynamic valve deterioration of transcatheter aortic valve replacement (TAVR) surgery and surgical aortic bioprostheses in the treatment of severe, symptomatic aortic stenosis. Prof. Michael ...
PACIFIC-AF is a multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding phase 2 study comparing the safety of the oral FXIa inhibitor asundexian with apixaban in patients with atrial fibrillation. It was a pleasure to speak with Prof. Manesh Patel (...
The Groningen Intervention study for the Preservation of cardiac function with STS after STEMI (GIPS-IV) trial is a double-blind, randomized, placebo-controlled, multicenter trial. touchCARDIO speaks with Dr Marie-Sophie de Koning (University of Groningen, Groningen, The Netherlands) to discuss her presentation ...
The SODIUM-HF trial tested whether or not a reduction in dietary sodium reduces the incidence of heart failure. touchCARDIO speaks with Prof. Justin Ezekowitz (University of Alberta, Edmonton, Canada) to discuss his presentation on the SODIUM-HF study on the effect ...
The EMPULSE trial showed the effects of empagliflozin on symptoms, physical limitations and quality of life in patients hospitalized for acute heart failure. touchCARDIO speaks with Prof. Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, MO) to ...
The VALOR-HCM trial showed the benefits of mavacamten as an alternative to surgical septal myectomy or alcohol ablation in patients with severely symptomatic obstructive hypertrophic cardiomyopathy. It was a pleasure to speak with Prof. Milind Desai (Cleveland Clinic, Cleveland, OH) ...
touchCARDIO
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
